Pharmaceutical New Development 2011 - Prescription Pharmaceutical Sales Overview

• Publication date: February 2011

About This Report Prescription pharmaceutical sales in the world’s major industry s (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled USD 555bn in 2009, having grown by 6.3% during 2008–09, and at a growth rate (CAGR) of 5.6% between 2005 and 2009. What's Included in This Report? * Examines the prescription pharmaceutical sales growth trends across t...

About This Report

Prescription pharmaceutical sales in the world’s major industry s (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled USD 555bn in 2009, having grown by 6.3% during 2008–09, and at a growth rate (CAGR) of 5.6% between 2005 and 2009.

What's Included in This Report?


* Examines the prescription pharmaceutical sales growth trends across the various different therapy areas

* Assesses the leading prescription pharmaceutical brands across the each of the 12 major pharma industry s

* Profiles the leading multinational and domestic pharma industry players operating in each of the 12 major pharma industry s

* Analyzes the projection sales according to lifecycle stage of drug, molecule type, source of drug, geographical industry, therapy area and formulation

Key Market Facts

The US prescription pharmaceutical industry generated half (50.3%) of the sales of the 12 industry s analyzed, with USD 279bn in 2009, with sales having grown by 5.0% (CAGR, 2005–09) and 5.5% (2008–09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.
Pharma is set to loose approximately USD 108bn in sales due to the patent cliff during 2010–15, while the market is also feeling the affect of the recent global economic downturn. However, Pharma is implementing a number of strategies to drive sales and profitability going forward: product innovation, diversification and cost-containment.
Growth in the emerging industry s is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generic drugs and branded pharmaceuticals.

Why Should You Buy This Report?


* Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2015

* Quantify the size and growth of the 12 major pharmaceutical industries, analyzing key therapy areas, brands and firms

* Assess drivers and resistors of the prescription pharmaceutical industry

Pharmaceutical Industry

Summary
Introduction
Strategic scoping and focus
Key Findings
Pharmaceutical industry size in the 12 major industry s
Leading therapy areas in the 12 major industry s
Leading prescription pharmaceutical brands in the 12 major industry s
Leading pharmaceutical industry players in the 12 major industry s
Global drivers and resistors for sales growth of the leading pharmaceutical industry players out to 2015
Related reports
Upcoming related reports
2. HISTORICAL PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Pharmaceutical Industry Size
The US pharmaceutical industry while the largest will decline through 2015
Cost-containment policies throughout EUR pe translate in modest growth
Brand loyal Japan aims to boost its generics drugs market
Australia’s small pharmaceutical industry is also undertaking cost-cutting measures
The emerging industry s showed the fastest growth rates
Leading Therapy Areas
The CNS and cardiovascular industry s will experience sales declines out to 2015 due to increasing generic competition
Metabolic, oncology and oncology industry s driven by biologic sales growth
Chinese medicines are the fastest growing drug group
Leading Pharmaceutical Brands
Lipitor is to experience a dramatic loss in sales due to its looming patent expiry
Plavix is the market -leading antithrombotic and is supported by a wealth of post-launch data
Nexium growth is attributed to its gold standard status and extensive patient switching, but sales are projection to decline
Leading Pharmaceutical Firms
Pfizer
Merck & Co.
AstraZeneca
GlaxoSmithKline
Novartis
Sanofi-Aventis
Roche
Johnson & Johnson
Eli Lilly
Takeda
3. FORECAST PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
Definitions
Global drivers and resistors for sales growth of the top 50 pharmaceutical industry players out to 2015
The top 50 pharmaceutical industry players (excluding generics drugs firms ) will experience sales growth of only 1.1% per year out to 2015
Expiries will only just be offset by newly launched and core drugs
The pharmaceutical market 's biologic focus is growing
The market will derive the majority of its sales from external products by 2015
Growth in global industry s will more than offset sales decline in the US
Secondary care therapy areas are becoming a priority for pharma
Injectable drugs are set to drive industry growth
Blockbuster drug sales will decline during 2010–15
4. BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Datamonitor prescription pharmaceutical definition and therapy area classification